- FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma – Targeted Oncology
- Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy – Reuters
- Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy – Reuters
- Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy – Reuters